Skip to content
Homepage
Category:
Press Releases
Posted Date:
June 5, 2026
What Adults Should Know About Monitoring Blood Pressure Between Checkups
Written By: EIN Presswire
June 5, 2026
AI Straight Talk on TV Show from ‘Hands-On-Keyboard’ Engineer
Written By: EIN Presswire
June 5, 2026
Aqualia refuerza su liderazgo en innovación hídrica durante la IWA Leading Edge Conference 2026 en Houston
Written By: EIN Presswire
June 5, 2026
Coming Soon: Dr. Angel A. Diaz’s New Book Explains the Hidden War for Innovation, Security, and Power
Written By: EIN Presswire
June 5, 2026
What Travelers Should Know About Transportation Between Airports, Hotels, and Cruise Terminals
Written By: EIN Presswire
June 5, 2026
Hyperbaric Chamber Nashville: How HBOT, IV Therapy, and EBO2 Support Personalized Recovery Protocols
Written By: EIN Presswire
June 5, 2026
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
Biomea Fusion, Inc.
June 5, 2026
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Kailera Therapeutics, Inc.
June 5, 2026
DentaQuest Data Breach: Edelson Lechtzin LLP Launches Investigation Into Exposure of Personal Information
Edelson Lechtzin LLP
June 5, 2026
Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism
Oban BioPharma, Inc.
June 5, 2026
Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
S&P Dow Jones Indices
June 5, 2026
Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026
NOVO NORDISK INC.
June 5, 2026
Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes
AMERICAN DIABETES ASSOCIATION
June 5, 2026
Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate
Ambrosia Biosciences
June 5, 2026
Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial
Precision Diabetes, Inc.
June 5, 2026
Prev
1
…
2,775
2,776
2,777